Evidence map›Paper›PMID 34461607›Full record

ArticleAging2021

m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.

Xiongpei Huang, Zecheng Qiu, Liusheng Li, Bin Chen, Peiyuan Huang

Abstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  4. Decoding mGenes & diseases · 2024
    Review
  5. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.Apoptosis : an international journal on programmed cell death · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Recent Advances in RNA mCancer treatment and research · 2023
    Article
  10. mFrontiers in immunology · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Application of mJournal of oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiongpei HuangDepartment of Hepatological Surgery, Maoming People's Hospital, Maoming 525000, China.
Zecheng QiuDepartment of Hepatological Surgery, Maoming People's Hospital, Maoming 525000, China.
Liusheng LiDepartment of Hepatological Surgery, Maoming People's Hospital, Maoming 525000, China.
Bin ChenDepartment of Hepatological Surgery, Maoming People's Hospital, Maoming 525000, China.
Peiyuan HuangDepartment of Pharmacy, Gaozhou People's Hospital, Gaozhou 525200, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is increasing evidence of the epigenetic regulation of the immune response in cancer. However, the specific functions and mechanisms of RNA N6-methyladenosine (m6A) modification in the cell infiltration in the hepatocellular carcinoma (HCC) tumor microenvironment (TME) is unknown.

methodsWe systematically analyzed the m6A-modification patterns of 371 HCC samples based on 23 m6A regulators, and determined their correlation with TME cell-infiltrating characteristics. Principal-component analysis algorithms was used to calculate the m6Ascore and clarify the m6A-modification patterns of individual tumors.

resultsThree different m6A-modification patterns were identified in HCC, wherein the m6Acluster B and m6Acluster A had the best and worst prognosis, respectively. These three patterns had different TME cell infiltration characteristics and biological behavior. An m6A-scoring signature was constructed to evaluate the m6A-modification patterns within individual tumors. A low m6Ascore was associated with a low overall survival and high clinical stage. Moreover, the m6A-scoring signature was characterized by distinct immunotherapeutic landscapes; a high m6A score indicated a higher immune checkpoint inhibitor score in the anti-PD-1 treatment alone, anti-CTLA-4 treatment alone, or combined anti-CTLA-4/PD-1 treatment cohorts, which reflected significant treatment and clinical benefits.

conclusionsOur study highlights the significant role of the m6A modification in the HCC TME. A scoring signature to clarify the individual m6A-modification pattern would help us understand the HCC TME infiltration characterization and, thus, would guide the selection of more effective immunotherapeutic strategies.

Indexed as

Epigenesis, GeneticGene Expression Regulation, NeoplasticTumor MicroenvironmentAlgorithmsBiomarkers, TumorCarcinoma, HepatocellularCohort StudiesCTLA-4 AntigenHumansImmunityImmunotherapyLiverLiver NeoplasmsMethylationMethyltransferasesPrincipal Component AnalysisBiomarkers, TumorCTLA-4 AntigenMethyltransferasesMETTL3 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNAhepatocellular carcinomaimmunotherapym6Amethylationtumor microenvironment

Identifiers

PMID34461607
PMCPMC8436903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.